Cox2 vs'Other NSAID Use in Children with JRA

1
Cox-2 vs.Other NSAID Use in Children with JRA

• Data from a cohort study, Beth Gottlieb, MD,
  Asst. Professor of Pediatrics, Schneider
  Childrens Hospital, New Hyde Park, NY

Kathleen A. Haines, MD Section Chief, Pediatric
Immunology Section of Pediatric Rheumatology and
Immunology Hackensack University Medical
Center Hackensack, NJ
2
Long Term Outcome Study of Children with JRA

• Prospective observational, multi-center study of
  children with JRA enrolled at onset
• Purpose was to collect data on outcomes of the
  various treatments used by pediatric
  rheumatologists
• Non-interventional study
• Support was obtained from the Arthritis
  Foundation

3
Long Term Outcome Study of Children with JRA

• Rheumatologists participated in an IRB-approved
  study
• Enrolled patients within 6 weeks of diagnosis
• Treatment was initiated according to the treating
  MDs usual practice
• At enrollment and on an annual basis, data
  including physical exam, treatment given, side
  effects of treatment and outcome measures were
  recorded and sent to the coordinating center
• Two cohorts were available for study
• Cohort 1 -- diagnosed between 1996-1999
• Data collected by Suzanne Bowyer, MD, James
  Whitcomb Riley Childrens Hospital, Indianapolis,
  IN
• Cohort 2 diagnosed from 2001 to present
• Data collected by Beth Gottlieb, MD, Schneider
  Childrens Hospital, New Hyde Park, NY

4
Long Term Outcome Study of Children with JRA

• 1115 patients are in the data base (from both
  cohorts)
• 60 Pauciarticular JRA
• 32 Polyarticular JRA
• 8 Systemic Onset JRA
• 35 patients were not classified
• 588 on NSAIDS had evaluable data
• 58 took a COX-2 inhibitor (rofecoxib or
  celecoxib)
• No serious adverse events were reported

5
Long Term Outcome Study of Children with JRA